aromasil has been researched along with sirolimus in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.56) | 29.6817 |
| 2010's | 36 (92.31) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Burris, HA; Campone, M; Deleu, I; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Lebwohl, D; Mukhopadhyay, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Rugo, HS; Sahmoud, T; Vittori, L; Xu, Z; Yardley, D | 1 |
| Johnston, SR | 1 |
| Beaver, JA; Park, BH | 1 |
| El-Hashimy, M; Horiguchi, J; Inaji, H; Ito, Y; Iwase, H; Iwata, H; Kuroi, K; Masuda, N; Mukai, H; Nakayama, T; Noguchi, S; Noh, WC; Ohno, S; Ohsumi, S; Panneerselvam, A; Park, BW; Puttawibul, P; Rai, Y; Sahmoud, T; Srimuninnimit, V; Taran, T; Tokuda, Y | 1 |
| Baselga, J; Burris, HA; Campone, M; Eakle, J; El-Hashimy, M; Geberth, M; Gnant, M; Hadji, P; Hart, LL; Hortobagyi, GN; Iwata, H; Lebwohl, D; Mukai, H; Noguchi, S; Piccart, M; Pritchard, KI; Rao, S; Rugo, HS; Sahmoud, T; Taran, T | 1 |
| Baselga, J; Bauly, H; Beck, JT; Bennett, L; Burris, HA; Chouinard, E; Gnant, M; Hortobagyi, GN; Komorowski, A; Lebrun, F; Neven, P; Noguchi, S; Petrakova, K; Piccart, M; Pritchard, KI; Ricci, JF; Rugo, HS; Sahmoud, T; Taran, T; Young, R | 1 |
| Dhillon, S | 1 |
| Athanassiadis, I; Nicolatou-Galitis, O; Nikolaidi, A; Papadopoulou, E; Sonis, S | 1 |
| Peterson, ME | 1 |
| Arena, F; Bachelot, T; Baselga, J; Burris, HA; Campone, M; Deleu, I; El-Hashimyt, M; Gnant, M; Hart, L; Héniquez, A; Hortobagyi, GN; Melichar, B; Noguchi, S; Panneerselvam, A; Piccart, M; Pistilli, B; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Shtivelband, M; Taran, T | 1 |
| Arteaga, C; Ciruelos, E; Cortes-Funes, H; Ghanem, I; Manso, L | 1 |
| Bachelot, T; Baselga, J; Beck, JT; Bennett, L; Burris, HA; Cahana, A; Campone, M; Gnant, M; Heng, DY; Horiguchi, J; Hortobagyi, GN; Komorowski, A; Neven, P; Noguchi, S; Nunzi, M; Piccart, M; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Taran, T; Zhang, J; Ziemiecki, R | 1 |
| Andre, F; Dieci, MV; Vicier, C | 1 |
| Arena, FP; Baselga, J; Burris, HA; Cahana, A; Campone, M; Erdkamp, F; Feng, W; Gnant, M; Harb, WA; Hortobagyi, GN; Lebwohl, D; Melichar, B; Noguchi, S; Petrakova, K; Piccart, M; Pistilli, B; Pritchard, KI; Rugo, HS; Taran, T; Yardley, DA | 1 |
| Mehta, A; Tripathy, D | 1 |
| Baselga, J; Bourgeois, H; Burris, HA; Campone, M; Csöszi, T; Dakhil, S; Gnant, M; Gonzalez Martin, A; Heng, D; Hortobagyi, GN; Ito, Y; Noguchi, S; Osborne, K; Panneerselvam, A; Piccart, M; Pritchard, KI; Puttawibul, P; Rugo, HS; Sahmoud, T; Srimuninnimit, V; Taran, T | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Beck, JT; Brechenmacher, T; Campone, M; Dakhil, S; Deleu, I; Douma, S; El-Hashimy, M; Geberth, M; Hart, L; Heng, DY; Hortobagyi, GN; Lebrun, F; Masuda, N; Melichar, B; Nunzi, M; Piccart, M; Pistilli, B; Ringeisen, F; Rugo, HS | 1 |
| Gilabert, M; Gonçalves, A; Launay, S | 1 |
| Láng, I; Rubovszky, G | 1 |
| Adunlin, G; Avancha, K; Diaby, V; Gluck, S; Lopes, G; Montero, AJ; Zeichner, SB | 1 |
| Adunlin, G; Ali, AA; Diaby, V; Tawk, R | 1 |
| de Boer, M; Lobbezoo, DJ; Smeets, RE; Tjan-Heijnen, VC; Vincent, J | 1 |
| Campone, M; Faust, E; Gao, H; Kageleiry, A; Signorovitch, JE; Yang, H; Zhang, J | 1 |
| Charalampous, P; Diamandi, M; Gkogkou, P; Ioannidis, G; Ioannou, R | 1 |
| Baselga, J; Burris, HA; Campone, M; Deleu, I; Fan, J; Feng, W; Gnant, M; Hortobagyi, GN; Ito, Y; Lebrun, F; Neven, P; Noguchi, S; Perez, A; Piccart, M; Pritchard, KI; Provencher, L; Rugo, HS; Shtivelband, M; Taran, T; Wu, C | 1 |
| Donders, F; Kuypers, D; Neven, P; Wolter, P | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Horiguchi, J; Ito, Y; Iwata, H; Kuroi, K; Masuda, N; Mori, A; Mukai, H; Noguchi, S; Ohno, N; Tokuda, Y | 1 |
| Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
| Bianchetti, S; Camozzi, M; Ciruelos, EM; Conte, P; Gavila, JG; Generali, D; Jerusalem, G; Lang, I; Lorizzo, K; Mardiak, J; Mariani, G; Martin, M; Michelotti, A; Montemurro, F; Naume, B; Neven, P; Simoncini, E; Tjan-Heijnen, VC | 1 |
| Awada, A; Baselga, J; Blum, JL; Ciruelos, EM; Cortes, J; Eaton, L; Ebbinghaus, S; Ewertz, M; Gause, C; Haddad, T; Im, E; Jones, MB; Mauro, D; Morales, SM; Moy, B; Pathiraja, K; Ruddy, KJ; Rugo, HS; Tan, AR; Vuylsteke, P | 1 |
| Afonso, N; Baselga, J; Blum, JL; Campone, M; Cortes, J; Denker, A; Eaton, L; Ferreira, M; Gause, CK; Im, E; Jones, MB; Mauro, DJ; Morales, SM; Musolino, A; Park, KH; Ro, J; Rugo, HS; Tan, AR; Trédan, O; Wang, Z | 1 |
| O'Shaughnessy, J; Royce, M; Thaddeus Beck, J | 1 |
| Barbolini, M; Bettelli, S; Caprera, C; Cascinu, S; Conte, PF; Filieri, ME; Guaitoli, G; Kaleci, S; Maiorana, A; Manfredini, S; Moscetti, L; Nasso, C; Omarini, C; Piacentini, F | 1 |
| Al Rabadi, L; Cook, MM; Kaempf, AJ; Mitri, ZI; Saraceni, MM; Savin, MA | 1 |
| Abdel-Razeq, H; Adhav, A; Aksoy, S; Bowles, J; Chae, Y; Chang, YC; Cinkir, HY; Im, SA; Im, YH; Jeong, J; Karabulut, B; Kim, SB; Lee, KS; Park, BW; Slimane, K; Xue, H | 1 |
11 review(s) available for aromasil and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Everolimus; Female; Humans; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Secondary Prevention; Sirolimus; Treatment Outcome | 2013 |
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Topics: Adult; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Exanthema; Female; Humans; Hyperglycemia; Pneumonia; Sirolimus; Stomatitis; Treatment Outcome | 2013 |
Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Topics: Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Everolimus; Female; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
[Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
[Combination of exemestane and everolimus may produce toxic side effects: a new treatment option for metastatic hormone-sensitive breast cancer].
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Fatigue; Female; Humans; Sirolimus | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Tamoxifen | 2018 |
16 trial(s) available for aromasil and sirolimus
| Article | Year |
|---|---|
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Recurrence; Sirolimus; Stomatitis; TOR Serine-Threonine Kinases | 2012 |
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Staging; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Treatment Outcome | 2012 |
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Quality of Life; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Topics: Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Collagen Type I; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Odds Ratio; Osteogenesis; Postmenopause; Procollagen; Proportional Hazards Models; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Drug Administration Schedule; Everolimus; Female; Health Status; Humans; Middle Aged; Odds Ratio; Postmenopause; Proportional Hazards Models; Quality of Life; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Health Status; Humans; Immunosuppressive Agents; Middle Aged; Placebos; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Surveys and Questionnaires; Treatment Outcome | 2013 |
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Everolimus; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2013 |
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; International Agencies; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Sirolimus; Survival Rate | 2013 |
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Sirolimus | 2014 |
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Thiocarbamates; Treatment Outcome | 2014 |
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Topics: Androstadienes; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Everolimus; Female; Humans; Placebos; Sirolimus; Survival Analysis | 2014 |
[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Everolimus; Female; Humans; Middle Aged; Postmenopause; Receptors, Estrogen; Sirolimus | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, e
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Everolimus; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus | 2016 |
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Receptors, Estrogen; Sirolimus; Stomatitis | 2017 |
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Retreatment; Sirolimus; Treatment Outcome | 2017 |
12 other study(ies) available for aromasil and sirolimus
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
BOLERO-2 - will this change practice in advanced breast cancer?
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Everolimus; Female; Humans; Immunosuppressive Agents; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.
Topics: Aged; Androstadienes; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Dexamethasone; Everolimus; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Oral Ulcer; Prospective Studies; Recurrence; Sirolimus; Stomatitis; Stomatitis, Aphthous; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Exanthema; Fatigue; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Placebos; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Steroid; Sirolimus; Stomatitis; Treatment Outcome; Viscera | 2013 |
[BOLERO -- another remarkable step in treatment of breast cancer].
Topics: Adult; Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Markov Chains; Neoplasm Metastasis; Sirolimus | 2014 |
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Databases, Factual; Europe; Everolimus; Female; Humans; Models, Economic; Sirolimus | 2014 |
Radiation-recall dermatitis with the everolimus/exemestane combination ten years after adjuvant whole-breast radiotherapy.
Topics: Androstadienes; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Everolimus; Female; Humans; Liver Neoplasms; Middle Aged; Neoplasms, Second Primary; Radiodermatitis; Radiotherapy, Adjuvant; Sirolimus | 2014 |
Everolimus in acute kidney injury in a patient with breast cancer: a case report.
Topics: Acute Kidney Injury; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Creatinine; Drug Therapy, Combination; Everolimus; Female; Humans; Sirolimus | 2014 |
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA Mutational Analysis; Everolimus; Female; Genes, Neoplasm; Humans; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Prospective Studies; Retrospective Studies; Sirolimus | 2018 |
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Everolimus; Female; Hormones; Humans; Receptor, ErbB-2; Retrospective Studies; Sirolimus | 2021 |
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Everolimus; Female; Humans; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Sirolimus | 2021 |